$2.8 Million in New Pharmaceutical Contracts in the Past 60 Days

ITASCA, IL–(EMWNews – July 28, 2008) – AtCor Medical

(ASX: ACG), the developer and marketer of the SphygmoCor system, which

measures central blood pressures and arterial stiffness non-invasively,

today announced that it has signed two new agreements to supply SphygmoCor

systems and clinical trial support services to a leading international

pharmaceutical company. The minimum total value of these contracts is USD

$1.6 million, the majority of which will be recognized in the current

fiscal year. These orders bring the minimum total value of the

pharmaceutical trial contracts secured by AtCor over the past 60 days to

over US $2.8 million.

Duncan Ross, CEO of AtCor Medical, said, “Our sales to pharmaceutical

companies continue to grow, and over the past two months we have executed

significant new contracts in the US and Europe. This demonstrates the

increasing importance of SphygmoCor as a tool for understanding drug

efficacy and mechanisms of action. We look forward to continuing to build

mutually beneficial relationships with our growing list of pharmaceutical

trial customers.”

Mr. Ross added, “The growing use of SphygmoCor systems in clinical trials

and increasing volume of publication concerning central blood pressures and

arterial stiffness indicate a move toward establishing a new standard for

cardiovascular risk assessment and management.”

About AtCor Medical

AtCor Medical develops and markets products for the early detection of

cardiovascular risk and management of cardiovascular disease. Its

technology allows researchers and clinicians to assess central blood

pressure non-invasively. The company’s SphygmoCor system visibly

identifies the effects of reflected blood pressure in the central aortic

pressure wave, effects which cannot be detected with standard blood

pressure monitoring. More than 1,400 SphygmoCor systems are currently in

use worldwide at major medical institutions, research institutions and in

various clinical trials with leading pharmaceutical companies. The

company’s technology has been featured in over 200 peer-reviewed studies

published in leading medical journals. AtCor has operations in the United

States, Australia and Europe. For further information, please visit our

web site at www.atcormedical.com

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions